The randomized, double-blind, placebo-controlled, trial will examine the effectiveness of Natrunix to treat rheumatoid arthritis compared to placebo in subjects already receiving stable but inadequate treatment with methotrexate (MTX). A total of 210 patients will be randomly distributed in equal numbers into three groups: including two different Natrunix dosages and a placebo group. Change in disease severity will be assessed at multiple time points according to the
Natrunix is a preparation using a monoclonal antibody indistinguishable from a naturally occurring antibody present in a healthy human. With billions of different antibodies circulating in the blood of healthy humans, identifying a single antibody molecule is technically challenging. Not a single antibody therapy marketed today or in the past was actually derived from a natural human antibody.
The Phase II study in rheumatoid arthritis is the culmination of
Natrunix specifically targets and neutralizes a substance-interleukin-1 (IL-1)-that is produced by the human body and is involved in many disease conditions. In chronic illness, such as rheumatoid arthritis, IL-1 can be a key part of the disease process. IL-1 can mediate the breakdown of joint synovium, bone remodelling, pain, and inflammation in the rheumatoid joint.
There are over 86,000 academic manuscripts and 6,600 review articles describing interleukin-1 (IL-1), making this substance among the most studied subjects in medicine. There are several marketed therapeutics targeting 'interleukin-1' (including KINERET, ARCALYST and ILARIS). Yet the term interleukin-1 actually refers to two different molecules-IL-1 and IL-1-that are produced at different times and places and play very different roles in disease. Remarkably, Natrunix is the only product candidate that exclusively targets and neutralizes the activity of IL-1, or the 'missing-link,' for the treatment of arthritis.
One in four adults, or over 50 million people in
About True Human Therapeutic Antibodies
About
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as 'may,' 'will,' 'should,' 'would,' 'could,' 'expects,' 'plans,' 'contemplate,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'projects,' 'intend' or 'continue' or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the 'Risk Factors' section of certain of our
Contact:
Email: wwei@xbiotech.com
Tel: 512-386-2900
(C) 2023 Electronic News Publishing, source